Announcements Trials
Browse Landscape

Phase

Phase 2 86Phase 1 86Phase 1/2 39Phase NA 31Phase 3 13Phase EARLY_PHASE1 6Phase 2/3 5Phase 4 4

Status

Completed 24Unknown 9Terminated 5Recruiting 4Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 47Breast 36Genitourinary 29Lymphoid 20Thoracic 18Other hematologic neoplasm 18CNS 13Gynecologic 12Endocrine 10Plasma cell 9Head & Neck 9Dermatologic 7Classical hematology 7Tumor-Agnostic 5Other 4NET 4Myeloid 4Other solid neoplasm 3Sarcoma 2Other neoplasm 1

Conditions

Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Myeloproliferative Disorders 1Mastocytosis, Systemic 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Blast Crisis 1Astrocytoma 1

Interventions

zanubrutinib 1trametinib 1nilotinib 1dabrafenib 1bosutinib 1avapritinib 1asciminib 1Rituximab 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Myeloid × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06748001 2026-02-09

Avapritinib Rollover Study

Blueprint Medicines Corporation

Phase 4 Recruiting
60 enrolled
Myeloid

Mastocytosis, Systemic

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
40 enrolled
LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡